TABLE 1.

Study subject data^a

Subject ID	Duration of study (mo)	Subtype(s)b	CD4 count (cells/mm3)		ΔCD4 (cells/mm3)
			Initial sample	Final sample
Dual infections
CMNYU107	36 (15 since dual infection)	01_AE-36_cpx URF/G	526	184	−342
CMNYU129	33 (24 since dual infection)	F2/CRF02_AG	603	337	−266
CMNYU6518	60 (57 since dual infection)	01_AE-36_cpx URF/01_AE-36_cpx URF	345	389	44
CMNYU6544	53 (47 since dual infection)	CRF02_AG-F2 URF/CRF02_AG	479	289	−190
Singly infected controls
CMNYU40	24	NDc	624	719	95
CMNYU110d	30	02_AG	393	220	−173
CMNYU113d	27	ND	964	355	−609
CMNYU122	36	02_AG	334	208	−126
CMNYU128d	36	02_AG	389	230	−159
CMNYU133	21	F2	923	592	−331
CMNYU153d	30	H	300	279	−21
CMNYU157	21	ND	373	306	−67
CMNYU161	30	ND	408	185	−223
CMNYU164d	27	02_AG	865	746	−119
CMNYU6489	30	A	421	126	−295
CMNYU6490	21	CRF11_cpx	338	209	−129
CMNYU6495	24	ND	347	231	−116
CMNYU6500	27	A	371	274	−97
CMNYU166	76	ND	534	313	−221
CMNYU179	77	02_AG	515	404	−111
CMNYU6504	65	ND	516	86	−430
CMNYU6537	51	02_AG-A1 URF	725	329	−396
CMNYU6540	53	ND	1180	520	−660
CMNYU6542d	51	02_AG-F2 URF	1206	599	−607
CMNYU6553	52	ND	503	239	−264
CMNYU6556	52	02_AG-F2-A1 URF	428	174	−254
CMNYU6561	51	ND	482	475	−7

^aSubjects shown in boldface comprise the long-duration control group.

^bSubtyping was done for C1C2 region of env.

^cND, not done.

^dUsed as controls for IC₅₀ analysis.